Daiichi Sankyo has announced a collaboration with ... Together the partners will work on digital solutions to prevent AF, which if adequately detected and treated, could prevent around 7,000 ...

Japan’s Daiichi Sankyo has joined an open innovation research ... companies are sitting on – are an invaluable asset. A digital health passport is an app, or online certification, that ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Prosecutors on Friday called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan ...

Daiichi Sankyo was founded in 2005 and operates in Chuo, Japan. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry belongs to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...